Oral Wegovy Tracker

What oral Wegovy is and how it differs from the injectable pen

Wegovy has been available for years as a once-weekly injectable pen, but on December 22, 2025, the FDA approved a tablet version of the same active ingredient, semaglutide, at a 25 mg once-daily maintenance dose. Novo Nordisk, the manufacturer, described it as the first and only oral GLP-1 receptor agonist approved for weight loss in adults, and the company expected the pill to reach US pharmacies in early January 2026. The FDA-approved prescribing information for Wegovy, revised in February 2026, lists tablets as an approved dosage form alongside the long-approved injection under the same drug application.

Per the FDA label, Wegovy tablets are indicated, along with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight who have at least one weight-related condition, and to reduce the risk of major cardiovascular events such as cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with established cardiovascular disease and either obesity or overweight. The label notes that two other approved uses of Wegovy, the pediatric weight-management indication for ages 12 and up and the liver-fibrosis (MASH) indication, remain approved only for the injection, not the tablet. The label also advises against combining Wegovy tablets or injection with other semaglutide-containing products or any other GLP-1 receptor agonist. The approval was supported by the OASIS phase 3 trial program, in which the 25 mg oral dose produced a mean weight loss of 16.6% over 64 weeks compared with placebo among adherent participants, together with cardiovascular outcomes data from the SELECT trial.

Because the tablet and the injection are the same underlying compound, Pokii groups them together as "Wegovy" when you view your medication levels by compound, while still logging and displaying them as the separate products they are, "Wegovy" and "Wegovy Pill," in your day-to-day history.

The label's dosing schedule and how the tablet is taken

The FDA label lays out a fixed titration schedule for Wegovy tablets before reaching the maintenance dose. Per Table 2 of the label, the schedule is 1.5 mg once daily on days 1 through 30, 4 mg once daily on days 31 through 60, 9 mg once daily on days 61 through 90, and 25 mg once daily from day 91 onward as the maintenance dose. The label notes that if a dose isn't tolerated during titration, escalation may be delayed, and if the 25 mg maintenance dose isn't tolerated, switching to the 1.7 mg once-weekly Wegovy injection may be considered.

The label also specifies how the tablet is meant to be taken: one tablet by mouth, once daily, on an empty stomach, in the morning, with up to 4 ounces of plain water only and no other liquids, swallowed whole without splitting, crushing, chewing, or dissolving it. After taking the tablet, the label calls for waiting at least 30 minutes before eating food, drinking any other beverages, or taking other oral medications. The label states that more than one tablet should not be taken per day, and that a missed dose should simply be skipped, with the next dose taken the following day rather than doubling up. The label also describes defined protocols for switching between the two forms of Wegovy, such as starting 25 mg tablets one week after stopping the 2.4 mg injection, or starting the 2.4 mg injection the day after stopping 25 mg tablets. These are label facts, not instructions from Pokii, which is a tracking and education tool and does not prescribe or recommend dosing.

Common side effects reported on the label

The FDA label lists the adverse reactions reported in at least 5% of patients on Wegovy tablets as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (burping), hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis.

The label also carries a boxed warning about the risk of thyroid C-cell tumors, based on findings in rodent studies where the relevance to humans hasn't been determined, and it lists warnings and precautions for acute pancreatitis, acute gallbladder disease, hypoglycemia when used with insulin or insulin secretagogues, acute kidney injury related to volume depletion, severe gastrointestinal reactions, hypersensitivity reactions including anaphylaxis and angioedema, complications of diabetic retinopathy, increased heart rate, and pulmonary aspiration risk during anesthesia or deep sedation. Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in anyone with known hypersensitivity to semaglutide or to the excipients in the tablet or injection.

What Pokii supports for oral Wegovy

Pokii's built-in medication library already includes "Wegovy Pill" as its own entry, distinct from injectable "Wegovy," so switching between the pill and the pen, or tracking both at different points in your history, doesn't require setting up a custom medication. During onboarding, Pokii asks whether your medication is injectable, oral, or unsure, and it carries that distinction through the rest of the app.

Because Wegovy tablets aren't injected, Pokii's oral dose logging skips the injection-specific fields, the injection site body map and pain slider, that only apply to shots. Oral doses are still logged with date, time, medicine, dose, and notes, and every entry keeps a full edit history, the same as injectable shots get. Flexible schedules apply to oral Wegovy as well: schedules can be set by interval or by selected weekdays, with per-weekday doses, a custom next-dose date, and a reminder time, which fits the tablet's once-daily pattern as easily as it fits a once-weekly injection.

Pokii's projected medication level charts, dose history, side-effect check-ins, and reminders all work the same way for oral Wegovy as they do for any other medication in the built-in library. For anyone who wants more control, Pokii's custom medication profiles include an oral toggle plus pharmacokinetic fields, such as half-life, Tmax, and bioavailability, though the built-in Wegovy Pill entry doesn't require any of that manual setup to start logging. As with every medication in Pokii, this is a tracking and education tool: it does not provide medical advice, diagnosis, or treatment, and its projected medication levels are educational models rather than lab results or dosing guidance.